Home Search

Epidyolex - search results

If you're not happy with the results, please do another search
GW Pharmaceuticals - Epidyolex

Epidyolex Receives European Commission Approval

GW Pharmaceuticals has announced it has received marketing authorisation for Epidyolex (not a typo) for treating certain conditions in all 28 EU countries as...
Australian medical cannabis approvals

TGA Medical Cannabis Approvals Update

Figures from Australia's Therapeutic Goods Administration indicate the agency is being kept busy with SAS Category B approvals for medicinal cannabis. Australia's Special Access Scheme...
GW Pharmaceuticals

New GW Pharma Facility Construction Kicks Off

GW Pharmaceuticals' parent has announced construction of a new major cannabinoid manufacturing facility at the UK's Kent Science Park has commenced. GW Pharma is the...
Emyria CBD trial

Australia’s Emyria Readies For CBD Trial

Another Australian company eyeing the country's low-dose, prescription-free cannabidiol market is clinical-stage biotech company Emyria Limited (ASX: EMD). Last year we reported Australia’s Cann Group...
Epidyolex approved for tuberous sclerosis complex (TSC) in the UK

CBD Medicine Given TSC Green Light In The UK

Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has announced it has received approval in the UK for the use of Epidyolex to manage seizures associated with...
Medical cannabis research in Australia

More Cash For Australian Medical Cannabis Research

The Australian Federal Government's recently handed down 2021-22 Budget included $1.5 million for a trial exploring personalised medicinal cannabis dosing in cancer patients. Awarded via...
GW Pharmaceuticals

GW Pharma Receives Queen’s Award For Cannabinoid Work

In what may be a first for a medical cannabis company, GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in the Innovation...
Jazz Pharmaceuticals and GW Pharma

Jazz Pharmaceuticals To Acquire GW Pharma

Jazz Pharmaceuticals is to acquire cannabinoid medicine manufacturer GW Pharmaceuticals for a whopping sum. Founded in 1998, GW Pharmaceuticals manufactures CBD-based Epidiolex, which is marketed...
Epidiolex sales - cannabidiol

Epidiolex A Cash Machine For GW Pharmaceuticals

GW Pharmaceuticals estimates its net product sales for 2020 to have reached approximately USD $526 million - and its cannabidiol medicine made up the...
Canopy Growth vs. GW Pharmaceuticals

Cannabidiol CO2 Extraction Patent Action Launched

Canada's Canopy Growth is taking on the UK's GW Pharmaceuticals over a widely used cannabidiol extraction method. The company recently filed its complaint in the...
Advertisement
Hemp Seed